Cohort 4 is evaluating zolbetuximab in combination with FOLFOX and nivolumab as first-line treatment in patients with HER2-negative, metastatic GC/GEJC with intermediate-to-high CLDN18.2 expression. This evidence concerns the gene CLDN18 and gastric cancer.